SEI Investments
ESPR

SEI Investments’s Esperion Therapeutics ESPR Stock Holding History

SEI Investments’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$205K Sell
64,925
-51,304
-44% -$144K ﹤0.01% 3031
2026
Q1 		$318K Buy
116,229
+40,237
+53% +$127K ﹤0.01% 2805
2025
Q4 		$281K Sell
75,992
-1,759
-2% -$5.68K ﹤0.01% 2772
2025
Q3 		$206K Buy
+77,751
New +$150K ﹤0.01% 2602
2025
Q1 		– Sell
-41,878
Closed -$92.1K – 2784
2024
Q4 		$92.1K Buy
41,878
+3,322
+9% +$7.75K ﹤0.01% 2598
2024
Q3 		$63.6K Buy
+38,556
New +$77.9K ﹤0.01% 2613
2023
Q4 		– Sell
-13,633
Closed -$13.4K – 2629
2023
Q3 		$13.4K Sell
13,633
-7,346
-35% -$10.6K ﹤0.01% 2613
2023
Q2 		$29.2K Hold
20,979
– – ﹤0.01% 2639
2023
Q1 		$33.4K Buy
20,979
+9,242
+79% +$47.7K ﹤0.01% 2646
2022
Q4 		$73.1K Sell
11,737
-880
-7% -$6.29K ﹤0.01% 2465
2022
Q3 		$85K Buy
+12,617
New +$86.6K ﹤0.01% 2585
2021
Q1 		– Sell
-13,258
Closed -$345K – 2491
2020
Q4 		$345K Sell
13,258
-116,748
-90% -$3.5M ﹤0.01% 2145
2020
Q3 		$4.83M Sell
130,006
-8,571
-6% -$339K 0.01% 884
2020
Q2 		$7.11M Buy
138,577
+33,138
+31% +$1.39M 0.02% 701
2020
Q1 		$3.32M Buy
105,439
+24,987
+31% +$1.32M 0.01% 933
2019
Q4 		$4.8M Buy
+80,452
New +$3.62M 0.01% 938
2019
Q1 		– Sell
-19
Closed -$1K – 2924
2018
Q4 		$1K Hold
19
– – ﹤0.01% 2622
2018
Q3 		$1K Sell
19
-81
-81% -$3.72K ﹤0.01% 2498
2018
Q2 		$4K Sell
100
-1,675
-94% -$84.6K ﹤0.01% 3196
2018
Q1 		$128K Buy
1,775
+615
+53% +$45.2K ﹤0.01% 2047
2017
Q4 		$76K Buy
1,160
+140
+14% +$7.54K ﹤0.01% 2228
2017
Q3 		$51K Buy
+1,020
New +$49.2K ﹤0.01% 2268
2015
Q4 		– Sell
-5,182
Closed -$122K – 2561
2015
Q3 		$122K Buy
5,182
+5,143
+13,187% +$323K ﹤0.01% 1727
2015
Q2 		$3K Buy
+39
New +$3.82K ﹤0.01% 2050

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

SEI Investments's ESPR Position: Q2 2026 in Review

SEI Investments reduced its Esperion Therapeutics (ESPR) stake by 44% in Q2 2026, selling an estimated $144K and leaving 64,925 shares worth $205K. The position accounts for ﹤0.01% of the portfolio, ranked #3031.

SEI Investments first reported a position in ESPR in Q2 2015 and has held it in 24 quarters since. The position peaked at $7.11M in Q2 2020. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • SEI Investments held 64,925 shares of Esperion Therapeutics worth $205K as of Q2 2026.
  • SEI Investments sold 51,304 Esperion Therapeutics shares in Q2 2026, an estimated $144K.
  • Esperion Therapeutics made up ﹤0.01% of SEI Investments's portfolio in Q2 2026, its #3031 holding.
  • SEI Investments first reported a position in Esperion Therapeutics in Q2 2015 and has held it in 24 quarters since.
  • SEI Investments's Esperion Therapeutics position peaked at $7.11M in Q2 2020.
  • 191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on SEI Investments's 13F filing for Q2 2026, filed 14 Aug 2026.